Treatment Action Group (TAG) released an overview of TB research data reported at CROI 2024. Highlights include the results of several phase II TB prevention and treatment trials. Among these were a study to evaluate a H56:IC31, vaccine candidate for the prevention of TB recurrence and a study to evaluate quabodepistat, a new TB drug with a novel mechanism of action.
A summary of major findings and TAG’s analysis are available here.
SEE ALSO:
Source : Treatment Action Group
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.